COBI: Contributing Factors to Local Bioimpedance Spectroscopy

Mode Sensors AS (Industry)
Overall Status
Recruiting ID
Oslo University Hospital (Other)

Study Details

Study Description

Brief Summary

This is an exploratory interventional study. The aim of the investigation is to identify and quantify contributing factors to local bioimpedance spectroscopy (BIS) measured by a wearable sensor patch, particularly the effect of fluid shifts caused by postural changes and lower body negative pressure (LBNP).

Condition or Disease Intervention/Treatment Phase
  • Device: Wearable bioimpedance sensor

Detailed Description

The investigational devices (patches) will perform near-continuous measurements of multifrequency bioimpedance (BIS), temperature, and body orientation (accelerometer) during the entire period of wear (2 days). Patches will be mounted at the upper body (back and thorax) and calf. The primary objective is to assess the effect of prolonged lower body negative pressure (LBNP) on the BIS of the calf. The target population is healthy volunteers between 18-50 years old.

Study Design

Study Type:
Anticipated Enrollment :
50 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Assessment of Contributing Factors to Local Bioimpedance Spectroscopy Using a Wearable Sensor: An Intervention Study
Anticipated Study Start Date :
Sep 4, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Wearable bioimpedance sensor

All subjects will use the investigational device and undergo several interventions: lower body negative pressure (3-40 minutes at 30 mmHg), posture intervention, and pressure intervention.

Device: Wearable bioimpedance sensor
The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.

Outcome Measures

Primary Outcome Measures

  1. Relative change in extracellular resistance of the calf from t0 to t1 (immediately before and after 40 minutes of LBNP at 30 mmHg), measured by the investigational bioimpedance device [40 minutes]

    Relative change in extracellular resistance at the calf from before to after 40 minutes of lower body negative pressure, to assess the effect of prolonged LBNP.

Secondary Outcome Measures

  1. Change in extracellular resistance at the upper back following postural changes, measured by the investigational bioimpedance device. [6 hours]

    Relative change in extracellular resistance at the upper back following changes in posture

  2. Changes in extracellular resistance at the upper back following application of three different external pressures. [2 hours]

    Mean differences in extracellular resistance of the upper back, when the subject lays in a supine position on three different surfaces. Extracellular resistance is measured by the investigational bioimpedance device.

  3. Frequency and severity of adverse device effects [3 days]

    To assess the safety of the investigational device in healthy volunteers

Eligibility Criteria


Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • 18 to 50 years of age, at the time of signing the informed consent

  • Overtly healthy as determined by medical evaluation including medical history, physical examination and focused cardiac ultrasound.

  • Use of adequate birth control for women of childbearing potential. Inclusion is possible when an acceptable effective contraceptive measure is used (combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence).

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:
  • Known allergies or skin sensitivities to electrode hydrogel and/or acrylic adhesives

  • Breached skin at patch mounting area.

  • Implantable pulse generators such as pacemakers and defibrillators, and/or use of other electrical medical equipment for which an interaction effect with the investigational device cannot be ruled out.

  • Planned magnetic resonance (MR) imaging during the investigation period

  • Any medical condition limiting physical exertional capacity or requiring regular medication (allergy and contraceptives excepted).

  • Pregnancy

  • Breastfeeding

  • History of syncope (syncope of presumed vasovagal nature with known precipitating factor excepted).

  • Any known cardiac disease that, at the investigator's discretion, warrants exclusion from the study, including but not limited to cardiac arrhythmia, esophageal varices, and aneurysms.

Contacts and Locations


Site City State Country Postal Code
1 Physiology lab. Aker hospital, Oslo University Hospital Oslo Norway 0586

Sponsors and Collaborators

  • Mode Sensors AS
  • Oslo University Hospital


  • Study Director: Sigve N Aas, PhD, Mode Sensors AS
  • Principal Investigator: Lars Ø Høiseth, PhD, Oslo University Hospital

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Mode Sensors AS Identifier:
Other Study ID Numbers:
  • DOC1040A COBI
First Posted:
Aug 21, 2023
Last Update Posted:
Aug 25, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Mode Sensors AS
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2023